A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty

Takeda80 enrolled

Overview

The main aim is to see how leuprolide works to treat central precocious puberty in children. Participants will receive an injection of leuprorelin acetate depot 11.25 mg every 12 weeks during 6 months and will visit their study clinic 6 times to complete some assessments.

The drug being tested in this study is called leuprorelin acetate depot 3M. Leuprorelin acetate depot 3M will be tested to treat children who have central precocious puberty. This study will look at the efficacy and safety of leuprorelin acetate depot 3M in the treatment of CPP. The study will enroll approximately 80 participants with CPP. Participants with a bodyweight of ≥ 20 kg will receive the recommended dose of leuprorelin acetate depot 3M in a 24 weeks Treatment Period followed by a 12 weeks Post-treatment follow-up period. Participants will be assigned to the following drug administration: • Leuprorelin Acetate Depot 3M 11.25 mg Participants will receive leuprorelin acetate depot 3M 11.25 mg as subcutaneous (SC) injection on Weeks 0, 12, and 24. The gonadotropin-releasing hormone agonist (GnRHa) stimulation, basal luteinizing hormone (LH), and follicle-stimulating hormone (FSH) levels will be tested pre-dose of every SC injection of the study drug or at premature termination. This multi-center trial will be conducted in China. The overall time to participate in this study is 38 weeks. Participants will make a follow-up visit to the site at approximately 12 weeks after the last dose of study treatment.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Central Precocious Puberty

Interventions

Leuprorelin Acetate Depot 3MDRUG

Leuprorelin Acetate Depot 3M SC injections.

Eligibility

Sex: ALLMax age: 10 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Maximum age to participate is this study is up to 10 years (child). Early appearance of secondary sexual characteristics: Girls ≤8 years, Boys ≤9years 2. Body weight ≥20 kg 3. According to the National Consensus Statement in China (2015), CPP is diagnosed when secondary sexual characteristics appeared before the age of 8 years in girls and 9 years in boys, a peak LH level \>5.0 IU/L with LH/FSH \>0.6 in stimulating test; evidence of gonadal development by ultrasonography (multiple ovarian follicles ≥4 mm in any ovary or uterine enlargement in females or testicular volume ≥4 mL in males); advanced bone age (BA) ≥1 year; linear growth acceleration with higher growth velocity (GV) than normal children. BA is determined by Greulich and Pyle standards or TW3 standards at screening. Exclusion Criteria: 1. The participant has received GnRHa treatment in a previous clinical study or as a therapeutic agent. 2. The participant has a history or clinical manifestations of significant adrenal or thyroid diseases or intracranial tumor OR has a history of malignant disease. 3. The participant has a history of hypersensitivity or allergies to leuprorelin, or related compounds including any excipients of the compound. 4. The participant has a diagnosis of peripheral precocious puberty.

Locations (5)

Beijing Children's Hospital, Capital Medical University

Beijing, Beijing Municipality, China

the First A liated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China

The Hospital attached by the Torigji Medical College, Huazhong Science and Technology University.

Wuhan, Hubei, China

Provincial Hospital Affiliated to Shandong First Medical University

Jinan, Shandong, China

Outcomes

Primary Outcomes

Percentage of Participants With Peak Luteinizing Hormone (LH) Suppression in Gonadotropin-Releasing Hormone (GnRH) Stimulation at Week 24

The LH suppression was defined as LH peak value in GnRH stimulation ≤3.0 international unit per liter (IU/L).

Time frame: Week 24

Secondary Outcomes

Percentage of Participants With Tanner Stage Regression or No Progression at Week 24

Tanner Stage was used to measure pubertal development. Tanner Stage was based on progression through 5-stages. The progression was defined as either breast/genitals or pubic hair score had increased score compared with baseline score. Otherwise, the status was classified as regression or no progression. Baseline is defined as the assessment prior to the first dose of study drug.

Time frame: Baseline and Week 24

Concentrations of Basal Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH)

Plasma LH and FSH peak concentrations under GnRH stimulation were assessed.

Time frame: Baseline, Weeks 24 and 36

Percentage of Participants With Decreased Ratio of Bone Age Over Chronological Age at Week 24

Bone age was determined by Greulich and Pyle standards or Tanner-Whitehouse 3 (TW3) standards.

Time frame: Baseline and Week 24

Percentage of Participants With Decreased First Morning Voided (FMV) Urinary Gonadotropin (Gn) at Week 24

Time frame: Baseline and Week 24

Number of Participants With Treatment-Emergent Adverse Events (TEAE)

An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. TEAE is defined as an AE with an onset that occurs after receiving study drug.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.